

Diagnostik und Therapie primärer ZNS-Lymphome (s. 8–12)

S. Seidel, V. Nilius-Eliliwi

Literatur:

1. Ostrom QT et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. *Neuro Oncol* 2021; 23(12 Suppl 2):iii1-iii105
2. Mendez JS et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. *Neuro Oncol* 2018; 20(5): 687–94
3. Farrall AL & Smith JR. Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study. *Cancers* 2021; 13(3): 403
4. Shiels MS et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. *Br J Haematol* 2016; 174(3): 417–24
5. Houillier C et al. Management and outcome of primary CNS lymphoma in the modern era. *Neurology* 2020; 94(10): e1027 LP-e39
6. Krebs S et al. Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review. *Ann Lymphoma* 2021;5
7. Fischer L et al. The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. *Haematologica* 2006; 91(3): 429–30
8. Fischer L et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. *Neurology* 2008; 71(14): 1102–8
9. Baraniskin A & Schroers R. Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL. *Cancers (Basel)* 2021; 13(11)
10. Scheichel F et al. Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study. *BMC Cancer* 2021; 21(1): 754
11. Camilleri-Broët S et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucémies et Autres Maladies du Sang (GOELAMS). *Am J Clin Pathol* 1998; 110(5): 607–12
12. Montesinos-Rongen M et al. Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System. *Cancers* 2021; 13(24)_ 6334
13. Hoang-Xuan K et al. European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System Lymphoma (PCNSL). *Neuro Oncol* 2022; noac196
14. Margold M et al. The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. *Neuro Oncol* 2021; 23(12): 2076–84
15. Henry JM et al. Primary malignant lymphomas of the central nervous system. *Cancer* 1974; 34(4): 1293–302
16. Bataille B et al. Primary intracerebral malignant lymphoma: report of 248 cases. *J Neurosurg* 2000; 92(2): 261–6

17. DeAngelis LM et al. Combined modality therapy for primary CNS lymphoma. *J Clin Oncol* 1992; 10(4): 635–43
18. Weller M et al. Surgery for primary CNS lymphoma? Challenging a paradigm. *Neuro Oncol* 2012; 14(12): 1481–4
19. Rae AI et al. Craniotomy and Survival for Primary Central Nervous System Lymphoma. *Neurosurgery* 2019; 84(4): 935–44
20. Jahr G et al. The role of surgery in intracranial PCNSL. *Neurosurg Rev* 2018; 41(4): 1037–44
21. Cloney MB et al. The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. *J Neurooncol* 2017; 132(1): 189–97
22. Nelson DF et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. *Int J Radiat Oncol Biol Phys* 1992; 23(1): 9–17
23. O'Brien P et al. Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma. *J Clin Oncol* 2000; 18(3): 519
24. DeAngelis LM et al. Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10. *J Clin Oncol* 2002; 20(24): 4643–8
25. Poortmans PM et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. *J Clin Oncol* 2003; 21(24): 4483–8
26. Abrey LE et al. Treatment for primary CNS lymphoma: the next step. *J Clin Oncol* 2000; 18(17): 3144–50
27. Omuro AMP et al. Delayed neurotoxicity in primary central nervous system lymphoma. *Arch Neurol* 2005; 62(10): 1595–600
28. Thiel E et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. *Lancet Oncol* 2010; 11(11): 1036–47
29. Herrlinger U et al. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. *J Cancer Res Clin Oncol* 2017; 143(9): 1815–21
30. Morris PG et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome. *J Clin Oncol* 2013; 31(31): 3971–9
31. Rubenstein JL et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). *J Clin Oncol* 2013; 31(25): 3061–8
32. Pels H et al. Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. *J Clin Oncol* 2003; 21(24): 4489–95
33. Juergens A et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. *Ann Neurol* 2010; 67(2): 182–9

34. Seidel S et al. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis. *Neurol Res Pract* 2019; 1(1): 1–9
35. Schorb et al. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. *Bone Marrow Transplant* 2017; 52(8): 1113–9
36. Schorb E et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. *Blood Adv* 2020; 4(14): 3378–81
37. Illerhaus G et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. *Lancet Haematol* 2016; 3(8): e388–e97
38. Ferreri AJM et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematol* 2017; 4(11): e510–e23
39. Houillier C et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: Results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. *J Clin Oncol* 2019; 37(10): 823–33
40. Batchelor T et al. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance). *J Clin Oncol* 2021; 39(15_suppl): 7506
41. Ferreri AJM et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. *Lancet Haematol* 2016; 3(5): e217–27
42. Ferreri AJM et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. *Leukemia* 2022; 36(7): 1870–8
43. Bromberg JEC et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. *Lancet Oncol* 2019; 20(2): 216–28
44. Schmitt AM et al. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis. *Hematol Oncol* 2019; 37(5): 548–57
45. Kasenda B et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. *Leukemia* 2017; 31(12): 2623–9
46. Soussain C et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. *Haematologica* 2012; 97(11): 1751–6
47. Soussain C et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. *J Clin Oncol* 2008; 26(15): 2512–8
48. Seidel S et al. High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity. *Cancers (Basel)* 2022; 14(9)

49. Ambady P et al. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. *Ann Lymphoma* 2021; 5: 23
 50. Schaff LR & Grommes C. Update on Novel Therapeutics for Primary CNS Lymphoma. *Cancers (Basel)* 2021; 13(21)
 51. Seidel S et al. Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma. *Neurology* 2020; 95(23): e3138-e3144
-

Diagnose von Hirnmetastasen-Rezidiven und therapiebedingten MRT-Veränderungen mittels PET (S. 13–16)

M. Wollring, J.-M. Werner, P. Lohmann, G. R. Fink, K.-J. Langen, N. Galldiks

Literatur:

1. Le Rhun E et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. *Ann Oncol* 2021; 32(11): 1332–47
2. Tawbi HA et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *N Engl J Med* 2018; 379(8): 722–30
3. Tawbi HA et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. *Lancet Oncol* 2021; 22(12): 1692–704
4. Langen KJ, Galldiks N, Hattingen E, Shah NJ. Advances in neuro-oncology imaging. *Nat Rev Neurol* 2017; 13(5): 279–89
5. Brown PD et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. *Lancet Oncol* 2017; 18(8): 1049–60
6. Galldiks N et al. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. *Neuro Oncol* 2020; 22(1): 17–30
7. Galldiks N et al. PET imaging in patients with brain metastasis-report of the RANO/PET group. *Neuro Oncol* 2019; 21(5): 585–95
8. Martin AM et al. Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. *JAMA Oncol* 2018; 4(8): 1123–24
9. Galldiks N, Kocher M, Langen KJ. Pseudoprogression after glioma therapy: an update. *Expert Rev Neurother* 2017; 17(11): 1109–15
10. Minniti G et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. *Radiat Oncol* 2011; (6): 48
11. Wolchok JD et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 2009; 15: 7412–20
12. Okada H et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. *Lancet Oncol* 2015; 16(15): e534–542

13. Preusser M et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. *Nat Rev Neurol* 2015; 11(9): 504–14
14. Roth P, Valavanis A, Weller M. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. *Neuro Oncol* 2017; 19(3): 454–56
15. Albert NL et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol* 2016; 18(9): 1199–208
16. Shields AF et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. *Nat Med* 1998; 4(11): 1334–36
17. Terakawa Y et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. *J Nucl Med* 2008; 49(5): 694–99
18. Tsuyuguchi N et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? *J Neurosurg* 2003; 98(5): 1056–64
19. Minamimoto R et al. Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment. *PloS one* 2015; 10(7): e0132515
20. Govaerts CW et al. (11)C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases. *Br J Radiol* 2021; 94(1125): 20210275
21. Yomo S, Oguchi K. Prospective study of (11)C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment. *BMC cancer* 2017; 17(1): 713
22. Lizarraga KJ et al. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. *J Nucl Med* 2014; 55(1): 30–36
23. Cicone F et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. *Eur J Nucl Med Mol Imaging* 2015; 42(1): 103–11
24. Tomura N et al. Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among (11)C-Methionine-PET, FDG-PET, MR Permeability Imaging, and MRI-ADC-Preliminary Results. *AJNR Am J Neuroradiol* 2017; 38(8): 1520–27
25. Galldiks N et al. Role of O-(2-18F-Fluoroethyl)-L-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. *J Nucl Med* 2012; 53(9): 1367–74
26. Ceccon G et al. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. *Neuro Oncol* 2017; 19(2): 281–88
27. Romagna A et al. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET-PET overcome diagnostic uncertainties? *Radiat Oncol* 2016; 11(1): 139
28. Lohmann P et al. Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase (18)F-FET PET accuracy without dynamic scans. *Eur Radiol* 2017; 27(7): 2916–27

29. Cicone F et al. Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET. *Neuro Oncol* 2021; 23(6): 1024–34
 30. Kebir S et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. *Neuro Oncol* 2016; 18(10): 1462–64
 31. Galldiks N et al. Treatment Monitoring of Immunotherapy and Targeted Therapy Using (18)F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. *J Nucl Med* 2021; 62(4): 464–70
 32. Nguyen NC et al. Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. *Front Oncol* 2018; 8: 18
 33. Kasten BB et al. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. *Theranostics* 2019; 9(17): 5085–104
 34. Wei W et al. Noninvasive PET Imaging of T cells. *Trends Cancer* 2018; 4(5): 359–73
 35. England CG et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. *J Nucl Med* 2017; 58(1): 162–68
 36. Chatterjee S, Lesniak WG, Nimmagadda S. Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. *Mol Imaging* 2017; 16: 1536012117718459
 37. Niemeijer AN et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. *Nat Commun* 2018; 9(1): 4664
 38. Niemeijer AN et al. First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer. *J Nucl Med* 2021
 39. Nienhuis PH et al. (18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study. *J Nucl Med* 2021
 40. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. *Radiology* 2016; 278(2): 563–77
 41. Lambin P et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nat Rev Clin Oncol* 2017; 14(12): 749–62
 42. Lambin P et al. Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer* 2012; 48(4): 441–46
 43. Hotta M, Minamimoto R, Miwa K. 11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier. *Sci Rep* 2019; 9(1): 15666
 44. Lohmann P et al. Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. *Neuroimage Clin* 2018; 20: 537–42
-

Aktueller Stand der Behandlung von intrazerebralen Gliomen im Erwachsenenalter – eine Übersicht (s. 17–24)

M. Nadji-Ohl, D. Sachs, G. Illerhaus, M. Münter, O. Ganslandt

Literatur:

1. Weller M et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet Oncol* 2017; 18(6): e315-e29
2. Lun M et al. The natural history of extracranial metastasis from glioblastoma multiforme. *J Neurooncol* 2011; 105(2): 261–73
3. Piccirilli M et al. Extra central nervous system metastases from cerebral glioblastoma multiforme in elderly patients. Clinico-pathological remarks on our series of seven cases and critical review of the literature. *Tumori* 2008; 94(1): 40–51
4. Mueller C et al. Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. *Cancer Res* 2014; 74(3): 818–28
5. Shaaban A et al. Spinal Metastasis of Cerebral Glioblastoma with Genetic Profile: Case Report and Review of Literature. *World Neurosurg* 2020; 143: 480–9
6. Louis DN et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol* 2016; 131(6): 803–20
7. Louis DN et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathol* 2020; 30(4): 844–56
8. Brat DJ et al. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". *Acta Neuropathol* 2018; 136(5): 805–10
9. Louis DN et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol* 2021; 23(8): 1231–51
10. Buckner JC et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. *N Engl J Med* 2016; 374(14): 1344–55
11. Cairncross G et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol* 2013; 31(3): 337–43
12. van den Bent MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol* 2013; 31(3): 344–50
13. Cancer Genome Atlas Research Network et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *N Engl J Med* 2015; 372(26): 2481–98
14. Erdem-Eraslan L et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. *J Clin Oncol* 2013; 31(3): 328–36

15. Pekmezci M et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. *Acta Neuropathol* 2017; 133(6): 1001–16
16. Aguilera D et al. Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib. *Pediatr Blood Cancer* 2016; 63(3): 541–3
17. Bautista F et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. *Pediatr Blood Cancer* 2014; 61(6): 1101–3
18. Lee EQ et al. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. *J Clin Oncol* 2016; 34(10): e87–9
19. Robinson GW et al. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. *BMC Cancer* 2014; 14: 258
20. Rush S et al. Brainstem ganglioglioma successfully treated with vemurafenib. *J Clin Oncol* 2013; 31(10): e159–60
21. Pichlmeier U et al. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. *Neuro Oncol* 2008; 10(6): 1025–34
22. Stummer W et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol* 2006; 7(5): 392–401
23. Jakola AS et al. Surgical resection versus watchful waiting in low-grade gliomas. *Ann Oncol* 2017; 28(8): 1942–8
24. Rahman M et al. The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. *J Neurosurg* 2017; 127(1): 123–31
25. Bell EH et al. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. *J Clin Oncol* 2020; 38(29): 3407–17
26. van den Bent MJ et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. *Lancet* 2017; 390(10103): 1645–53
27. Dono A et al. IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions. *Curr Oncol Rep* 2021; 23(2): 20
28. Baumert BG et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. *Lancet Oncol* 2016; 17(11): 1521–32
29. Shaw EG et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. *J Clin Oncol* 2012; 30(25): 3065–70
30. van den Bent MJ & Taal W. Are we done with dose-intense temozolomide in recurrent glioblastoma? *Neuro Oncol* 2014; 16(9): 1161–3
31. Etxaniz O et al. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. *J Neurooncol* 2017; 135(2): 273–84

32. Stupp R et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005; 352(10): 987–96
 33. Herrlinger U et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet* 2019; 393(10172): 678–88.
 34. Perry JR et al. Radiation plus Temozolomide in Patients with Glioblastoma. *N Engl J Med* 2017; 376(22): 2197
 35. Barani IJ & Larson DA. Radiation therapy of glioblastoma. *Cancer Treat Res* 2015; 163: 49–73
 36. Sarria GR et al. Intraoperative radiotherapy for glioblastoma: an international pooled analysis. *Radiother Oncol* 2020; 142: 162–7
 37. Stupp R et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. *Eur J Cancer* 2012; 48(14): 2192–202
 38. Shah PP et al. A systematic review of tumor treating fields therapy for high-grade gliomas. *J Neurooncol* 2020; 148(3): 433–43
 39. Seliger C et al. Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. *Int J Cancer* 2020; 146(3): 803–9
 40. Onken J et al. Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma. *Anticancer Res* 2017; 37(3): 1227–35
 41. Kast RE et al. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. *Oncotarget* 2014; 5(18): 8052–82
 42. Lookian PP et al. Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. *Int J Mol Sci* 2021; 22(7)
 43. Vanhauwaert D et al. Quality indicators in neuro-oncology: Review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey. *J Neurooncol* 2022; 157(2)
 44. Renovanz M et al. Glioma patients in outpatient care – optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial. *Trials* 2020; 21: 434
-

Diagnostik und Therapie des Hepatozellulären Karzinoms (S. 28–34)

M. Bathon, A. Vogel

Literatur:

1. Sung H et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; 71(3): 209–49
2. Siegel RL et al. Cancer statistics, 2022. *CA: A Cancer Journal for Clinicians* 2022; 72(1): 7–33
3. Jinjuvadia, R et al. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. *J Clin Gastroenterol* 2014; 48(2): 172–7
4. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF): Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome Langversion 3.0, 2022, AWMF-Registernummer: 032/053OL. (<https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliaere-karzinome/>). Zugegriffen: 23.08.2022
5. Dang H et al. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. *Hepatology* 2020; 71(6): 1910–22
6. Yin J et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. *J Clin Oncol* 2013; 31(29): 3647–55
7. Lee YJ et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging—a systematic review and meta-analysis. *Radiology* 2015; 275(1): 97–109
8. Kim YY et al. Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018. *Radiology* 2019; 291(1): 72–80
9. Childs A et al., Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. *Br J Cancer* 2021; 125(10): 1350–5
10. Wongjarupong N et al. BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study. *HPB (Oxford)* 2021; 23(5): 762–9
11. Johnson PJ et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. *J Clin Oncol* 2015; 33(6): 550–8
12. Reig M et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol* 2022; 76(3): 681–93
13. Yang A et al. Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database. *Oncotarget* 2017; 8(57): 97428–38
14. Mazzaferro V et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. *Lancet Oncol* 2020; 21(7): 947–56
15. Zhou Y et al. Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review. *Surg Oncol* 2014; 23(4): 236–42
16. Citterio D et al. Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. *JAMA Surg* 2016; 151(9): 846–53
17. Heimbach JK et al. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* 2018; 67(1): 358–80

18. Brown KT et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. *J Clin Oncol* 2016; 34(17): 2046–53
19. Chow PKH et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. *J Clin Oncol* 2018; 36(19): 1913–21
20. Finn RS et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). *J Clin Oncol* 2021; 39(3_suppl): 267
21. Galle PR et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. *Lancet Oncol* 2021; 22(7): 991–1001
22. Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; 359(4): 378–90
23. Kudo M et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018; 391(10126): 1163–73
24. Vogel A & Martinelli E. ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. *Ann Oncol* 2021; 32(6): 801–5
25. Kelley RK et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2022; 23(8): 995–1008
26. Abou-Alfa GK et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. *J Clin Oncol* 2022; 40(4_suppl): 379